ACE inhibitors in heart failure work by blocking the RAAS, which reduces angiotensin II–mediated vasoconstriction and aldosterone-driven sodium and water retention. This leads to vasodilation and a drop in afterload, making it easier for the heart to eject blood and improving forward flow. Over time, this neurohormonal modulation also slows adverse remodeling and lowers mortality in patients with reduced ejection fraction HF. The reason this option is the best is that it captures both the hemodynamic effect (reduced afterload) and the important clinical outcome (reduced mortality), along with a crucial safety consideration: renal function and potassium need to be monitored because ACE inhibitors can raise creatinine and potassium levels. This combination reflects both efficacy and real-world management. The other statements don’t fit as well. ACE inhibitors do have a role in heart failure, not none. Their main action is afterload reduction rather than preload, though venodilation can modestly affect preload but is not the primary effect. While they can raise potassium, saying they always worsen potassium is an oversimplification; monitoring is essential to manage this risk, rather than assuming a universal worsening.

A safe, effective plan for stable cardiovascular patients combines aerobic activity with resistance training and progresses gradually. Aim for moderate-intensity aerobic exercise most days, totaling about 150 minutes per week (such as brisk walking, cycling, or swimming), distributed across several days. Add resistance training 2–3 days per week to improve muscular strength, starting with light weights and 1–2 sets of 8–12 repetitions, then gradually increasing as tolerated. Include a warm-up and cool-down, and monitor for warning signs like chest pain, undue shortness of breath, or dizziness, adjusting intensity or seeking medical clearance if needed. This balanced approach provides both cardiovascular and muscular benefits and is safer for most stable patients. Stretching alone doesn’t improve aerobic fitness, and skipping resistance training misses important strength gains; exercising rigorously every day or not exercising at all are not recommended.

D-dimer testing is most useful for ruling out thromboembolism rather than confirming it. The test is very sensitive for clot formation and breakdown, so a negative result strongly argues against a PE or DVT in patients who are low risk. This gives a high negative predictive value, meaning you can often avoid imaging in those low‑probability cases. However, D-dimer has low specificity. Many non-thrombotic factors—such as infection, inflammation, cancer, recent surgery, age, or pregnancy—can raise D-dimer levels. Because of that, a positive result does not confirm PE or DVT; it simply raises suspicion and usually leads to imaging to establish a diagnosis. In practice, you combine pretest probability with D-dimer results: if risk is low and the D-dimer is negative, you can rule out clot. If risk is intermediate or high, or if the D-dimer is positive, you proceed to definitive imaging (like CT pulmonary angiography for PE or compression ultrasound for DVT). Age-adjusted thresholds can help improve specificity in older patients.

Widened pulse pressure in aortic regurgitation happens because the regurgitant flow causes a large gap between systolic and diastolic pressures. During diastole, blood leaks backward from the aorta into the left ventricle, pulling the aortic diastolic pressure down. At the same time, the ventricle responds by increasing stroke volume, which can raise the systolic pressure. The combination is a high systolic pressure paired with a low diastolic pressure, producing a noticeably widened pulse pressure. This pattern isn’t seen with a narrowed pulse pressure, which occurs when stroke volume is reduced or systemic vascular resistance is high. It also doesn’t fit a scenario where diastolic pressure remains high with low systolic, or where there’s no change at all.